Krill Oil Supplementation Improves Dyslipidemia and Lowers Body Weight in Mice Fed a High-Fat Diet Through Activation of AMP-Activated Protein Kinase

Journal of Medicinal Food

Volumn 19, Issue 12, 2016, Pages 1120-1129

  Yang, Goowon ^a   Lee, Jihyun ^a   Lee, Sangsu ^b   Kwak, Dongyun ^b   Choe, Wonchae ^a   Kang, Insug ^a   Kim, Sung Soo ^a   Ha, Joohun ^a,c  

^a Kyung Hee University Hospital   (South Korea)

^b R and D Center PowerCubeSemi 901 103 Bucheon Technopark Ssangyong III   (South Korea)

^c Kyung Hee University   (South Korea)

Author keywords

AMPK; krill oil; LDL cholesterol; liver steatosis; long chain polyunsaturated omega 3 fatty acids; obesity

Indexed keywords

ADIPONECTIN; EDIBLE OIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KRILL OIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FATTY ACID; OIL; OMEGA 3 FATTY ACID;

ABDOMINAL FAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIE; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DIET INDUCED OBESITY; DYSLIPIDEMIA; ENZYME ACTIVATION; FAT CONTENT; FAT MASS; FATTY ACID SYNTHESIS; FATTY LIVER; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOBLOTTING; IN VIVO STUDY; LIPID DIET; LIPID HOMEOSTASIS; LIPID METABOLISM; METABOLIC PARAMETERS; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CHEMISTRY; DIETARY SUPPLEMENT; DRUG EFFECTS; DYSLIPIDEMIAS; KRILL; LIVER; MALE; METABOLISM;

ABDOMINAL FAT; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CHOLESTEROL, LDL; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; ENZYME ACTIVATION; EUPHAUSIACEA; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FATTY LIVER; LIPID METABOLISM; LIVER; MALE; MICE; MICE, INBRED C57BL; OILS; TRIGLYCERIDES; WEIGHT GAIN;

EID: 85006713335     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2016.3720     Document Type: Article

References (38)

1. Grundy SM: Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-636.
2. Lifschitz C: Early life factors influencing the risk of obesity. Pediatr Gastroenterol Hepatol Nutr 2015;18:217-223.
3. Khandekar MJ, Cohen P, Spiegelman BM: Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011;11:886-895.
4. Mellendijk L, Wiesmann M, Kiliaan AJ: Impact of nutrition on cerebral circulation and cognition in the metabolic syndrome. Nutrients 2015;7:9416-9439.
5. Cicero AF, Colletti A: Role of phytochemicals in the management of metabolic syndrome. Phytomedicine 2016;23:1134-1144.
6. Weylandt KH, Serini S, Chen YQ, et al. : Omega-3 polyunsaturated fatty acids: The way forward in times of mixed evidence. Biomed Res Int 2015;2015:143109.
7. Xiao SU, Tanalgo P, Bustos M, Dass CR: The effect of krill oil and n-3 polyunsaturated fatty acids on human osteosarcoma cell proliferation and migration. Curr Drug Targets 2015 [Epub ahead of print].
8. Backes JM, Howard PA: Krill oil for cardiovascular risk prevention: Is it for real Hosp Pharm 2014;49:907-912.
9. Ramprasath VR, Eyal I, Zchut S, Jones PJ: Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil. Lipids Health Dis 2013;12:178.
10. Kakoti BB, Hernandez-Ontiveros DG, Kataki MS, Shah K, Pathak Y, Panguluri SK: Resveratrol and omega-3 fatty acid: Its implications in cardiovascular diseases. Front Cardiovasc Med 2015;2:38.
11. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003;23:e20-e30.
12. Kris-Etherton PM, Harris WS, Appel LJ: Omega-3 fatty acids and cardiovascular disease: New recommendations from the American Heart Association. Arterioscler Thromb Vasc Biol 2003;23:151-152.
13. Kwantes JM, Grundmann O: A brief review of krill oil history, research, and the commercial market. J Diet Suppl 2015;12:23-35.
14. Kohler A, Sarkkinen E, Tapola N, Niskanen T, Bruheim I: Bioavailability of fatty acids from krill oil, krill meal and fish oil in healthy subject-A randomized, single-dose, cross-over trial. Lipids Health Dis 2015;14:19.
15. Ferramosca A, Conte A, Zara V: Krill oil ameliorates mitochondrial dysfunctions in rats treated with high-fat diet. Biomed Res Int 2015;2015:645984.
16. Burri L, Johnsen L: Krill products: An overview of animal studies. Nutrients 2015;7:3300-3321.
17. Burri L, Hoem N, Banni S, Berge K: Marine omega-3 phospholipids: Metabolism and biological activities. Int J Mol Sci 2012;13:15401-15419.
18. Winther B, Hoem N, Berge K, Reubsaet L: Elucidation of phosphatidylcholine composition in krill oil extracted from Euphausia superba. Lipids 2011;46:25-36.
19. Lagarde M, Bernoud N, Brossard N, et al. : Lysophosphatidylcholine as a preferred carrier form of docosahexaenoic acid to the brain. J Mol Neurosci 2001;16:201-204; discussion 215-221.
20. Wijendran V, Huang MC, Diau GY, Boehm G, Nathanielsz PW, Brenna JT: Efficacy of dietary arachidonic acid provided as triglyceride or phospholipid as substrates for brain arachidonic acid accretion in baboon neonates. Pediatr Res 2002;51:265-272.
21. Maki KC, Reeves MS, Farmer M, et al. : Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women. Nutr Res 2009;29:609-615.
22. Hardie DG: AMP-activated protein kinase: Maintaining energy homeostasis at the cellular and whole-body levels. Annu Rev Nutr 2014;34:31-55.
23. Hardie DG, Ashford ML: AMPK: Regulating energy balance at the cellular and whole body levels. Physiology (Bethesda) 2014;29:99-107.
24. Antonioli L, Colucci R, Pellegrini C, et al. : The AMPK enzymecomplex: From the regulation of cellular energy homeostasis to a possible new molecular target in the management of chronic inflammatory disorders. Expert Opin Ther Targets 2015;20:1-13.
25. Ha J, Guan KL, Kim J: AMPK and autophagy in glucose/glycogen metabolism. Mol Aspects Med 2015;46:46-62.
26. Hardie DG: AMPK: A target for drugs and natural products with effects on both diabetes and cancer. Diabetes 2013;62: 2164-2172.
27. Gasparrini M, Giampieri F, Alvarez Suarez JM, et al. : AMPK as a new attractive therapeutic target for disease prevention: The role of dietary compounds. Curr Drug Targets 2016;17:865-889.
28. Ramesh M, Vepuri SB, Oosthuizen F, Soliman ME: Adenosine monophosphate-activated protein kinase (AMPK) as a diverse therapeutic target: A computational perspective. Appl Biochem Biotechnol 2016;178:810-830.
29. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK: AMPK activation: A therapeutic target for type 2 diabetes Diabetes Metab Syndr Obes 2014;7:241-253.
30. Yang J, Shih II, Tzeng Y, Wang S: Production and purification of protease from a Bacillus subtilis that can deproteinize crustacean wastes. Enzyme Microb Technol 2000;26:406-413.
31. Vazquez-Martin A, Corominas-Faja B, Oliveras-Ferraros C, Cufi S, Dalla Venezia N, Menendez JA: Serine79-phosphorylated acetyl-CoA carboxylase, a downstream target of AMPK, localizes to the mitotic spindle poles and the cytokinesis furrow. Cell Cycle 2013;12:1639-1641.
32. Zhou G, Myers R, Li Y, et al. : Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
33. Hostetler HA, Kier AB, Schroeder F: Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor alpha (PPARa). Biochemistry 2006;45:7669-7681.
34. Takeuchi Y, Yahagi N, Izumida Y, et al. : Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. J Biol Chem 2010;285:11681-11691.
35. Hirasawa A, Tsumaya K, Awaji T, et al. : Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005;11:90-94.
36. Kim N, Lee JO, Lee HJ, et al. : Endogenous ligand for GPR120, docosahexaenoic acid, exerts benign metabolic effects on the skeletal muscles via AMP-activated protein kinase pathway. J Biol Chem 2015;290:20438-20447.
37. Hardie DG, Alessi DR: LKB1 and AMPK and the cancermetabolism link-Ten years after. BMC Biol 2013;11:36.
38. Hawley SA, Pan DA, Mustard KJ, et al. : Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2005;2:9-19